A FEW WORDS ABOUT US

 

To new shores with customized discovery solutions

 

inSili.com offers an elite source of intellectual property and unique expertise for innovative pharmaceutical and biotechnological research and development.

 

We provide know-how and world-leading technology services for virtual screening of pharmacologically active molecular agents. Our clients are among the world's top pharmaceutical, chemical, biotechnology and cosmeceutical enterprises.

 

Founded in 2013 as an ETH spin-off company, inSili.com's exclusive technology platform, strong track record and solid partnerships enable a rennaissance of small-molecule drug discovery and provide the foundation for custom-tailored medicines of the future.

We provide premier scientific consulting and technology services for chemical and pharmaceutical R&D.

 

化学産業及び創薬研究のコンサルティングサービスを提供。

 

inSili.com は日本の製薬産業、化学産業、生命科学産業と長年に渡り信頼関係を築いており、高品質のサービスを提供いたしております。

WHAT WE DO

AUTOMATING DRUG DISCOVERY

 

We offer innovative molecular design & virtual screening solutions, enabling improved chemical and pharmaceutical R&D.

 

産業応用又は創薬研究の新規化合物デザインとバーチャルスクリーニング。

LEADS BY DESIGN

 

We create new chemical entities on demand, featuring multi-target activity profiles or designer selectivity.

 

ご希望の標的活性プロフィールを基に新規化合物を作成。

ARTIFICIAL INTELLIGENCE

 

We develop artificial intelligence systems enabling the discovery of bioactive chemical entities with desired properties.

 

人工知能システムによる生理活性を示す新規化合物を発見。

OUR TECHNOLOGY

 

inSili.com = adaptive innovation

 

inSili.com's founders created and defined the terms "scaffold-hopping" and "frequent-hitters" in drug discovery and developed industry-proven molecular design algorithms like CATS (Chemically Advanced Template Search) and DOGS (Design Of Genuine Structures).

 

Our groundbreaking CopyCATS™ molecular design technology permits rapid discovery of new chemical entities with desired properties and tailored polypharmacology.

 

inSili.com's unique Collection Of Bioactive Reference Analogs (COBRA™) and unrivaled macromolecular target prediction technique TIGER™ (Target Inference GEneRator) enable the "deorphaning" of bioactive agents like natural products and phenotypic screening hits, screening compound library design, target-oriented hit-to-lead expansion, and drug re-purposing.

The current version of TIGER considers up to 1,728 individual targets and target classes.

 

POOMA™ (PrOjection Of Molecular Attributes) software generates fitness landscapes for focused compound library design, and enables rapid data clustering for diversity analysis.

 

Own technology development and drug discovery projects continuously strengthen inSili.com's innovation potential.

OUR DISCOVERY PARTNERS

 

» Expert Opin. Drug Discov. 12, 271 (2017)

» Chem. Commun. 53, 2227 (2017)

» Chem. Commun. 52, 1135 (2016)

» Angew. Chem. Int. Ed. 55, 6789 (2016)

» Nature Chemistry 8, 531 (2016)

» Nature Chemistry 6, 1072 (2014)

» Proc. Natl. Acad. Sci. USA 111, 4067 (2014)

» Angew. Chem. Int. Ed. 53, 4244 (2014)

» Angew. Chem. Int. Ed. 52, 10006 (2013)

CONTACT US

inSili.com GmbH (Ltd Liab. Co.)

Segantinisteig 3, 8049 Zurich

Switzerland

PRESS RELEASES

inSili.com and KyoTex announce partnership (04-2015) - Read more

 

inSili.com and SARomics announce partnership (07-2014) - Read more

© Copyright 2017. All Rights Reserved. Disclaimer